Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011

Olaf Schoffer; Stefanie Schülein; Gerlinde Arand; Hans Arnholdt; Dieter Baaske; Ralf C. Bargou; Nikolaus Becker; Matthias W. Beckmann; Yves Bodack; Beatrix Böhme; Tayfun Bozkurt; Regine Breitsprecher; Andre Buchali; Elke Burger; Ulrike Burger; Klaus Dommisch; Gudrun Elsner; Karin Fernschild; Ulrike Flintzer; Uwe Funke; Michael Gerken; Hubert Göbel; Norbert Grobe; Vera Gumpp; Lucie Heinzerling; Lana Raffaela Kempfer; Alexander Kiani; Monika Klinkhammer-Schalke; Sabine Klöcking; Ute Kreibich; Katrin Knabner; Peter Kuhn; Stine Lutze; Uwe Mäder; Tanja Maisel; Jan Maschke; Martin Middeke; Andreas Neubauer; Antje Niedostatek; Anabelle Opazo-Saez; Christoph Peters; Beatrice Schell; Gerhard Schenkirsch; Harald Schmalenberg; Peter Schmidt; Constanze Schneider; Birgit Schubotz; Anika Seide; Paul Strecker; Sabine Taubenheim; Matthias Wackes; Steffen Weiß; Claudia Welke; Carmen Werner; Christian Wittekind; Jörg Wulff; Heike Zettl; Stefanie J. Klug

doi:10.1186/s12885-016-2963-0

Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011

Olaf Schoffer, Stefanie Schülein, Gerlinde Arand, Hans Arnholdt, Dieter Baaske, Ralf C. Bargou, Nikolaus Becker, Matthias W. Beckmann, Yves Bodack, Beatrix Böhme, Tayfun Bozkurt, Regine Breitsprecher, Andre Buchali, Elke Burger, Ulrike Burger, Klaus Dommisch, Gudrun Elsner, Karin Fernschild, Ulrike Flintzer, Uwe FunkeMichael Gerken, Hubert Göbel, Norbert Grobe, Vera Gumpp, Lucie Heinzerling, Lana Raffaela Kempfer, Alexander Kiani, Monika Klinkhammer-Schalke, Sabine Klöcking, Ute Kreibich, Katrin Knabner, Peter Kuhn, Stine Lutze, Uwe Mäder, Tanja Maisel, Jan Maschke, Martin Middeke, Andreas Neubauer, Antje Niedostatek, Anabelle Opazo-Saez, Christoph Peters, Beatrice Schell, Gerhard Schenkirsch, Harald Schmalenberg, Peter Schmidt, Constanze Schneider, Birgit Schubotz, Anika Seide, Paul Strecker, Sabine Taubenheim, Matthias Wackes, Steffen Weiß, Claudia Welke, Carmen Werner, Christian Wittekind, Jörg Wulff, Heike Zettl, Stefanie J. Klug

Chair of Epidemiology

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Background: Over the past two decades, there has been a rising trend in malignant melanoma incidence worldwide. In 2008, Germany introduced a nationwide skin cancer screening program starting at age 35. The aims of this study were to analyse the distribution of malignant melanoma tumour stages over time, as well as demographic and regional differences in stage distribution and survival of melanoma patients. Methods: Pooled data from 61 895 malignant melanoma patients diagnosed between 2002 and 2011 and documented in 28 German population-based and hospital-based clinical cancer registries were analysed using descriptive methods, joinpoint regression, logistic regression and relative survival. Results: The number of annually documented cases increased by 53.2% between 2002 (N = 4 779) and 2011 (N = 7 320). There was a statistically significant continuous positive trend in the proportion of stage UICC I cases diagnosed between 2002 and 2011, compared to a negative trend for stage UICC II. No trends were found for stages UICC III and IV respectively. Age (OR 0.97, 95% CI 0.97-0.97), sex (OR 1.18, 95% CI 1.11-1.25), date of diagnosis (OR 1.05, 95% CI 1.04-1.06), 'diagnosis during screening' (OR 3.24, 95% CI 2.50-4.19) and place of residence (OR 1.23, 95% CI 1.16-1.30) had a statistically significant influence on the tumour stage at diagnosis. The overall 5-year relative survival for invasive cases was 83.4% (95% CI 82.8-83.9%). Conclusions: No distinct changes in the distribution of malignant melanoma tumour stages among those aged 35 and older were seen that could be directly attributed to the introduction of skin cancer screening in 2008.

Original language	English
Article number	936
Journal	BMC Cancer
Volume	16
Issue number	1
DOIs	https://doi.org/10.1186/s12885-016-2963-0
State	Published - 5 Dec 2016

Keywords

Malignant melanoma
Skin cancer screening
Stage distribution
Survival analysis
TNM staging

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s12885-016-2963-0

Cite this

Schoffer, O., Schülein, S., Arand, G., Arnholdt, H., Baaske, D., Bargou, R. C., Becker, N., Beckmann, M. W., Bodack, Y., Böhme, B., Bozkurt, T., Breitsprecher, R., Buchali, A., Burger, E., Burger, U., Dommisch, K., Elsner, G., Fernschild, K., Flintzer, U., ... Klug, S. J. (2016). Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011. BMC Cancer, 16(1), Article 936. https://doi.org/10.1186/s12885-016-2963-0

@article{93479259beb24b4f929a82068542fced,

title = "Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011",

abstract = "Background: Over the past two decades, there has been a rising trend in malignant melanoma incidence worldwide. In 2008, Germany introduced a nationwide skin cancer screening program starting at age 35. The aims of this study were to analyse the distribution of malignant melanoma tumour stages over time, as well as demographic and regional differences in stage distribution and survival of melanoma patients. Methods: Pooled data from 61 895 malignant melanoma patients diagnosed between 2002 and 2011 and documented in 28 German population-based and hospital-based clinical cancer registries were analysed using descriptive methods, joinpoint regression, logistic regression and relative survival. Results: The number of annually documented cases increased by 53.2% between 2002 (N = 4 779) and 2011 (N = 7 320). There was a statistically significant continuous positive trend in the proportion of stage UICC I cases diagnosed between 2002 and 2011, compared to a negative trend for stage UICC II. No trends were found for stages UICC III and IV respectively. Age (OR 0.97, 95% CI 0.97-0.97), sex (OR 1.18, 95% CI 1.11-1.25), date of diagnosis (OR 1.05, 95% CI 1.04-1.06), 'diagnosis during screening' (OR 3.24, 95% CI 2.50-4.19) and place of residence (OR 1.23, 95% CI 1.16-1.30) had a statistically significant influence on the tumour stage at diagnosis. The overall 5-year relative survival for invasive cases was 83.4% (95% CI 82.8-83.9%). Conclusions: No distinct changes in the distribution of malignant melanoma tumour stages among those aged 35 and older were seen that could be directly attributed to the introduction of skin cancer screening in 2008.",

keywords = "Malignant melanoma, Skin cancer screening, Stage distribution, Survival analysis, TNM staging",

author = "Olaf Schoffer and Stefanie Sch{\"u}lein and Gerlinde Arand and Hans Arnholdt and Dieter Baaske and Bargou, {Ralf C.} and Nikolaus Becker and Beckmann, {Matthias W.} and Yves Bodack and Beatrix B{\"o}hme and Tayfun Bozkurt and Regine Breitsprecher and Andre Buchali and Elke Burger and Ulrike Burger and Klaus Dommisch and Gudrun Elsner and Karin Fernschild and Ulrike Flintzer and Uwe Funke and Michael Gerken and Hubert G{\"o}bel and Norbert Grobe and Vera Gumpp and Lucie Heinzerling and Kempfer, {Lana Raffaela} and Alexander Kiani and Monika Klinkhammer-Schalke and Sabine Kl{\"o}cking and Ute Kreibich and Katrin Knabner and Peter Kuhn and Stine Lutze and Uwe M{\"a}der and Tanja Maisel and Jan Maschke and Martin Middeke and Andreas Neubauer and Antje Niedostatek and Anabelle Opazo-Saez and Christoph Peters and Beatrice Schell and Gerhard Schenkirsch and Harald Schmalenberg and Peter Schmidt and Constanze Schneider and Birgit Schubotz and Anika Seide and Paul Strecker and Sabine Taubenheim and Matthias Wackes and Steffen Wei{\ss} and Claudia Welke and Carmen Werner and Christian Wittekind and J{\"o}rg Wulff and Heike Zettl and Klug, {Stefanie J.}",

note = "Publisher Copyright: {\textcopyright} 2016 The Author(s).",

year = "2016",

month = dec,

day = "5",

doi = "10.1186/s12885-016-2963-0",

language = "English",

volume = "16",

journal = "BMC Cancer",

issn = "1471-2407",

publisher = "BioMed Central Ltd.",

number = "1",

}

Schoffer, O, Schülein, S, Arand, G, Arnholdt, H, Baaske, D, Bargou, RC, Becker, N, Beckmann, MW, Bodack, Y, Böhme, B, Bozkurt, T, Breitsprecher, R, Buchali, A, Burger, E, Burger, U, Dommisch, K, Elsner, G, Fernschild, K, Flintzer, U, Funke, U, Gerken, M, Göbel, H, Grobe, N, Gumpp, V, Heinzerling, L, Kempfer, LR, Kiani, A, Klinkhammer-Schalke, M, Klöcking, S, Kreibich, U, Knabner, K, Kuhn, P, Lutze, S, Mäder, U, Maisel, T, Maschke, J, Middeke, M, Neubauer, A, Niedostatek, A, Opazo-Saez, A, Peters, C, Schell, B, Schenkirsch, G, Schmalenberg, H, Schmidt, P, Schneider, C, Schubotz, B, Seide, A, Strecker, P, Taubenheim, S, Wackes, M, Weiß, S, Welke, C, Werner, C, Wittekind, C, Wulff, J, Zettl, H & Klug, SJ 2016, 'Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011', BMC Cancer, vol. 16, no. 1, 936. https://doi.org/10.1186/s12885-016-2963-0

TY - JOUR

T1 - Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011

AU - Schoffer, Olaf

AU - Schülein, Stefanie

AU - Arand, Gerlinde

AU - Arnholdt, Hans

AU - Baaske, Dieter

AU - Bargou, Ralf C.

AU - Becker, Nikolaus

AU - Beckmann, Matthias W.

AU - Bodack, Yves

AU - Böhme, Beatrix

AU - Bozkurt, Tayfun

AU - Breitsprecher, Regine

AU - Buchali, Andre

AU - Burger, Elke

AU - Burger, Ulrike

AU - Dommisch, Klaus

AU - Elsner, Gudrun

AU - Fernschild, Karin

AU - Flintzer, Ulrike

AU - Funke, Uwe

AU - Gerken, Michael

AU - Göbel, Hubert

AU - Grobe, Norbert

AU - Gumpp, Vera

AU - Heinzerling, Lucie

AU - Kempfer, Lana Raffaela

AU - Kiani, Alexander

AU - Klinkhammer-Schalke, Monika

AU - Klöcking, Sabine

AU - Kreibich, Ute

AU - Knabner, Katrin

AU - Kuhn, Peter

AU - Lutze, Stine

AU - Mäder, Uwe

AU - Maisel, Tanja

AU - Maschke, Jan

AU - Middeke, Martin

AU - Neubauer, Andreas

AU - Niedostatek, Antje

AU - Opazo-Saez, Anabelle

AU - Peters, Christoph

AU - Schell, Beatrice

AU - Schenkirsch, Gerhard

AU - Schmalenberg, Harald

AU - Schmidt, Peter

AU - Schneider, Constanze

AU - Schubotz, Birgit

AU - Seide, Anika

AU - Strecker, Paul

AU - Taubenheim, Sabine

AU - Wackes, Matthias

AU - Weiß, Steffen

AU - Welke, Claudia

AU - Werner, Carmen

AU - Wittekind, Christian

AU - Wulff, Jörg

AU - Zettl, Heike

AU - Klug, Stefanie J.

PY - 2016/12/5

Y1 - 2016/12/5

N2 - Background: Over the past two decades, there has been a rising trend in malignant melanoma incidence worldwide. In 2008, Germany introduced a nationwide skin cancer screening program starting at age 35. The aims of this study were to analyse the distribution of malignant melanoma tumour stages over time, as well as demographic and regional differences in stage distribution and survival of melanoma patients. Methods: Pooled data from 61 895 malignant melanoma patients diagnosed between 2002 and 2011 and documented in 28 German population-based and hospital-based clinical cancer registries were analysed using descriptive methods, joinpoint regression, logistic regression and relative survival. Results: The number of annually documented cases increased by 53.2% between 2002 (N = 4 779) and 2011 (N = 7 320). There was a statistically significant continuous positive trend in the proportion of stage UICC I cases diagnosed between 2002 and 2011, compared to a negative trend for stage UICC II. No trends were found for stages UICC III and IV respectively. Age (OR 0.97, 95% CI 0.97-0.97), sex (OR 1.18, 95% CI 1.11-1.25), date of diagnosis (OR 1.05, 95% CI 1.04-1.06), 'diagnosis during screening' (OR 3.24, 95% CI 2.50-4.19) and place of residence (OR 1.23, 95% CI 1.16-1.30) had a statistically significant influence on the tumour stage at diagnosis. The overall 5-year relative survival for invasive cases was 83.4% (95% CI 82.8-83.9%). Conclusions: No distinct changes in the distribution of malignant melanoma tumour stages among those aged 35 and older were seen that could be directly attributed to the introduction of skin cancer screening in 2008.

AB - Background: Over the past two decades, there has been a rising trend in malignant melanoma incidence worldwide. In 2008, Germany introduced a nationwide skin cancer screening program starting at age 35. The aims of this study were to analyse the distribution of malignant melanoma tumour stages over time, as well as demographic and regional differences in stage distribution and survival of melanoma patients. Methods: Pooled data from 61 895 malignant melanoma patients diagnosed between 2002 and 2011 and documented in 28 German population-based and hospital-based clinical cancer registries were analysed using descriptive methods, joinpoint regression, logistic regression and relative survival. Results: The number of annually documented cases increased by 53.2% between 2002 (N = 4 779) and 2011 (N = 7 320). There was a statistically significant continuous positive trend in the proportion of stage UICC I cases diagnosed between 2002 and 2011, compared to a negative trend for stage UICC II. No trends were found for stages UICC III and IV respectively. Age (OR 0.97, 95% CI 0.97-0.97), sex (OR 1.18, 95% CI 1.11-1.25), date of diagnosis (OR 1.05, 95% CI 1.04-1.06), 'diagnosis during screening' (OR 3.24, 95% CI 2.50-4.19) and place of residence (OR 1.23, 95% CI 1.16-1.30) had a statistically significant influence on the tumour stage at diagnosis. The overall 5-year relative survival for invasive cases was 83.4% (95% CI 82.8-83.9%). Conclusions: No distinct changes in the distribution of malignant melanoma tumour stages among those aged 35 and older were seen that could be directly attributed to the introduction of skin cancer screening in 2008.

KW - Malignant melanoma

KW - Skin cancer screening

KW - Stage distribution

KW - Survival analysis

KW - TNM staging

UR - http://www.scopus.com/inward/record.url?scp=85000416138&partnerID=8YFLogxK

U2 - 10.1186/s12885-016-2963-0

DO - 10.1186/s12885-016-2963-0

M3 - Article

C2 - 27919243

AN - SCOPUS:85000416138

SN - 1471-2407

VL - 16

JO - BMC Cancer

JF - BMC Cancer

IS - 1

M1 - 936

ER -

Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this